|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fu SW, Lee W, Coffey C, Lean A, Wu X, Tan
X, Man YG and Brem RF: miRNAs as potential biomarkers in early
breast cancer detection following mammography. Cell Biosci.
6:62016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Porter P: ‘Westernizing’ women's risks?
Breast cancer in lower-income countries. N Engl J Med. 358:213–216.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beaglehole R and Yach D: Globalisation and
the prevention and control of non-communicable disease: The
neglected chronic diseases of adults. Lancet. 362:903–908. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parkin DM and Fernández LM: Use of
statistics to assess the global burden of breast cancer. Breast J.
12 Suppl 1:S70–S80. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Badar F, Faruqui ZS, Ashraf A and Uddin N:
Third world issues in breast cancer detection. J Pak Med Assoc.
57:137–140. 2007.PubMed/NCBI
|
|
7
|
Bray F, Ren JS, Masuyer E and Ferlay J:
Global estimates of cancer prevalence for 27 sites in the adult
population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakamura S, Yagata H, Ohno S, Yamaguchi H,
Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K and Suzuki E:
Multi-center study evaluating circulating tumor cells as a
surrogate for response to treatment and overall survival in
metastatic breast cancer. Breast Cancer. 17:199–204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gong Y, He T, Yang L, Yang G, Chen Y and
Zhang X: The role of miR-100 in regulating apoptosis of breast
cancer cells. Sci Rep. 5:116502015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weigelt B, Peterse JL and van 't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alonso DF, Ripoll GV, Garona J, Iannucci
NB and Gomez DE: Metastasis: Recent discoveries and novel
perioperative treatment strategies with particular interest in the
hemostatic compound desmopressin. Curr Pharm Biotechnol.
12:1974–1980. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nilsson I and Hoffmann I: Cell cycle
regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res.
4:107–114. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hydbring P and Badalian-Very G: Clinical
applications of microRNAs. F1000Res. 2:1362013.PubMed/NCBI
|
|
14
|
Gromak N: Intronic microRNAs: A crossroad
in gene regulation. Biochem Soc Trans. 40:759–761. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kosaka N, Iguchi H and Ochiya T:
Circulating microRNA in body fluid: A new potential biomarker for
cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pichler M and Calin GA: MicroRNAs in
cancer: From developmental genes in worms to their clinical
application in patients. Br J Cancer. 113:569–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Medina PP, Nolde M and Slack FJ: OncomiR
addiction in an in vivo model of microRNA-21-induced pre-B-cell
lymphoma. Nature. 467:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Obad S, dos Santos CO, Petri A, Heidenblad
M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, et al:
Silencing of microRNA families by seed-targeting tiny LNAs. Nat
Genet. 43:371–378. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saito Y, Liang G, Egger G, Friedman JM,
Chuang JC, Coetzee GA and Jones PA: Specific activation of
microRNA-127 with downregulation of the proto-oncogene BCL6 by
chromatin-modifying drugs in human cancer cells. Cancer Cell.
9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lujambio A, Calin GA, Villanueva A, Ropero
S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso
MS, Faller WJ, et al: A microRNA DNA methylation signature for
human cancer metastasis. Proc Natl Acad Sci USA. 105:pp.
13556–13561. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma L, Ma S, Zhao G, Yang L, Zhang P, Yi Q
and Cheng S: miR-708/LSD1 axis regulates the proliferation and
invasion of breast cancer cells. Cancer Med. 5:684–692. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van Jaarsveld MT, Helleman J, Berns EM and
Wiemer EA: MicroRNAs in ovarian cancer biology and therapy
resistance. Int J Biochem Cell Biol. 42:1282–1290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ni F, Gui Z, Guo Q, Hu Z, Wang X, Chen D
and Wang S: Downregulation of miR-362-5p inhibits proliferation,
migration and invasion of human breast cancer MCF7 cells. Oncol
Lett. 11:1155–1160. 2016.PubMed/NCBI
|
|
27
|
Zhang Y, Zhang HE and Liu Z: MicroRNA-147
suppresses proliferation, invasion and migration through the
AKT/mTOR signaling pathway in breast cancer. Oncol Lett.
11:405–410. 2016.PubMed/NCBI
|
|
28
|
Kai Y, Qiang C, Xinxin P, Miaomiao Z and
Kuailu L: Decreased miR-154 expression and its clinical
significance in human colorectal cancer. World J Surg Oncol.
13:1952015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin X, Yang Z, Zhang P and Shao G: miR-154
suppresses non-small cell lung cancer growth in vitro and in vivo.
Oncol Rep. 33:3053–3060. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xin C, Zhang H and Liu Z: miR-154
suppresses colorectal cancer cell growth and motility by targeting
TLR2. Mol Cell Biochem. 387:271–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu C, Shao P, Bao M, Li P, Zhou H, Cai H,
Cao Q, Tao L, Meng X, Ju X, et al: miR-154 inhibits prostate cancer
cell proliferation by targeting CCND2. Urol Oncol. 32:31.e9–e16.
2014. View Article : Google Scholar
|
|
32
|
Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai
H, Li P, Cao Q, Ju X, Meng X, et al: miR-154 inhibits EMT by
targeting HMGA2 in prostate cancer cells. Mol Cell Biochem.
379:69–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blobel CP: ADAMs: Key components in EGFR
signalling and development. Nat Rev Mol Cell Biol. 6:32–43. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Edwards DR, Handsley MM and Pennington CJ:
The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fritzsche FR, Wassermann K, Jung M, Tölle
A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K and
Kristiansen G: ADAM9 is highly expressed in renal cell cancer and
is associated with tumour progression. BMC Cancer. 8:1792008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fritzsche FR, Jung M, Tölle A, Wild P,
Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C,
et al: ADAM9 expression is a significant and independent prognostic
marker of PSA relapse in prostate cancer. Eur Urol. 54:1097–1106.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
O'Shea C, McKie N, Buggy Y, Duggan C, Hill
AD, McDermott E, O'Higgins N and Duffy MJ: Expression of ADAM-9
mRNA and protein in human breast cancer. Int J Cancer. 105:754–761.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tao K, Qian N, Tang Y, Ti Z, Song W, Cao D
and Dou K: Increased expression of a disintegrin and
metalloprotease-9 in hepatocellular carcinoma: Implications for
tumor progression and prognosis. Jpn J Clin Oncol. 40:645–651.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Grützmann R, Lüttges J, Sipos B, Ammerpohl
O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R,
Kalthoff H, et al: ADAM9 expression in pancreatic cancer is
associated with tumour type and is a prognostic factor in ductal
adenocarcinoma. Br J Cancer. 90:1053–1058. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang S, Wang X, Guo Q, Wang G, Han X, Li
X, Shi ZW and He W: MicroRNA-126 overexpression inhibits
proliferation and invasion in osteosarcoma cells. Technol Cancer
Res Treat. 15:NP49–NP59. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang C, Zhang Y, Ding W, Lin Y, Huang Z
and Luo Q: MiR-33a suppresses breast cancer cell proliferation and
metastasis by targeting ADAM9 and ROS1. Protein Cell. 6:881–889.
2015. View Article : Google Scholar : PubMed/NCBI
|
